Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $2.2 million.

  • Insight Molecular Diagnostics' Accumulated Expenses rose 1689.4% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 1689.4%. This contributed to the annual value of $1.9 million for FY2024, which is 1758.64% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Accumulated Expenses of $2.2 million as of Q3 2025, which was up 1689.4% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Accumulated Expenses ranged from a high of $4.1 million in Q3 2022 and a low of $1.3 million during Q2 2023
  • In the last 5 years, Insight Molecular Diagnostics' Accumulated Expenses had a median value of $2.2 million in 2025 and averaged $2.3 million.
  • In the last 5 years, Insight Molecular Diagnostics' Accumulated Expenses soared by 13828.96% in 2021 and then tumbled by 5765.92% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Accumulated Expenses stood at $2.8 million in 2021, then fell by 28.48% to $2.0 million in 2022, then dropped by 18.45% to $1.6 million in 2023, then grew by 17.59% to $1.9 million in 2024, then grew by 14.9% to $2.2 million in 2025.
  • Its Accumulated Expenses was $2.2 million in Q3 2025, compared to $1.5 million in Q2 2025 and $2.5 million in Q1 2025.